Vivo Capital LLC Boosts Stock Position in Savara Inc (NASDAQ:SVRA)

Vivo Capital LLC raised its stake in Savara Inc (NASDAQ:SVRA) by 9.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,088,323 shares of the company’s stock after purchasing an additional 174,974 shares during the period. Savara accounts for approximately 0.8% of Vivo Capital LLC’s investment portfolio, making the stock its 27th largest holding. Vivo Capital LLC’s holdings in Savara were worth $9,815,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of SVRA. Adage Capital Partners GP L.L.C. boosted its position in Savara by 30.9% in the third quarter. Adage Capital Partners GP L.L.C. now owns 7,938,551 shares of the company’s stock valued at $30,008,000 after buying an additional 1,874,000 shares during the last quarter. Jennison Associates LLC lifted its holdings in Savara by 44.6% in the third quarter. Jennison Associates LLC now owns 3,866,762 shares of the company’s stock valued at $14,616,000 after acquiring an additional 1,192,730 shares during the period. Polar Capital Holdings Plc acquired a new position in Savara in the third quarter valued at approximately $3,780,000. China Universal Asset Management Co. Ltd. acquired a new position in Savara in the fourth quarter valued at approximately $74,000. Finally, SG Americas Securities LLC lifted its holdings in Savara by 34.2% in the fourth quarter. SG Americas Securities LLC now owns 49,862 shares of the company’s stock valued at $234,000 after acquiring an additional 12,720 shares during the period. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Analyst Ratings Changes

SVRA has been the subject of several research analyst reports. Piper Sandler upped their target price on Savara from $7.00 to $16.00 and gave the stock an “overweight” rating in a research note on Monday, March 4th. JMP Securities reiterated a “market outperform” rating and set a $8.00 price target on shares of Savara in a research report on Monday. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $8.20.

Savara Price Performance

Shares of SVRA traded up $0.03 during trading hours on Thursday, hitting $5.02. 77,588 shares of the stock were exchanged, compared to its average volume of 865,050. The company has a debt-to-equity ratio of 0.19, a quick ratio of 15.66 and a current ratio of 15.66. The stock’s 50-day moving average price is $4.89 and its two-hundred day moving average price is $4.51. The company has a market cap of $693.66 million, a price-to-earnings ratio of -15.12 and a beta of 0.73. Savara Inc has a 12-month low of $1.86 and a 12-month high of $5.70.

Savara (NASDAQ:SVRA) last issued its earnings results on Thursday, March 7th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.02. Research analysts expect that Savara Inc will post -0.38 earnings per share for the current year.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.